An Open-Label Study Assessing the Safety and Efficacy of Naltrexone Sustained Release (SR) in Combination With Bupropion Sustained Release (SR) in Overweight and Obese, Nicotine-Dependent Subjects

NCT00563563 Phase 2 COMPLETED

The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of nicotine-dependence in overweight and obese subjects.

Details

Lead sponsor	Orexigen Therapeutics, Inc
Phase	Phase 2
Status	COMPLETED
Enrolment	30
Start date	2007-10
Completion	2008-09

Conditions

• Nicotine Dependence
• Overweight
• Obesity

Interventions

• NB32
• Ancillary therapy

Primary outcomes

• Assess rates of smoking cessation defined by continuous abstinence. — 12 weeks

Countries

United States